Aft Pharmaceuticals Ltd. · NZX:AFT
Aft Pharmaceuticals — NZSA Meeting 2017
15 slides from Aft Pharmaceuticals's conference presentation, Aug 21, 2017
Slide 1: A Small Fish in a Big Ocean: Surviving and Growing
For personal use only A Small Fish in a Big Ocean: Surviving and Growing Dr Hartley Atkinson M.Pharm [dist], PhD CEO and Founder
Slide 2: Important Notice
For personal use only IMPORTANT NOTICE This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of AFT. It is not prepared for any other purpose and must not be provided to any person other than the intended recipient. All amounts are disclosed in New
Slide 3: The Challenge and Our History
The Challenge and Our History AFT History Started in Garage in 1997 with $50K start-up capital Expanded out of NZ in to AU 2004 For personal use only Listed NZ & ASX December 2015 Why Small Companies are Looking Beyond NZ for Growth NZ market is tiny and Pharma is a global business Fixed development
Slide 4: Global OTC Analgesic Market and Pharma Market
For personal use only Global OTC Analgesic Market and Pharma Market NZSA Meeting 4 19 August 2017
Slide 5: Summary of AFT Business
SUMMARY OF AFT BUSINESS Established Business [1997] and growing AU & NZ Significant further potential growth in AU For personal use only • - Grow newly launched and existing OTCs • - Grow Maxigesic from Codeine switch Development of Key Innovative Products with Global Potential The most significant
Slide 6: Current Highlights
For personal use only CURRENT HIGHLIGHTS Countries that Maxigesic is now licensed in 124 Countries that Maxigesic is launched and sold in 9 Further launch orders being processed now Clinical studies AFT will have running in FY2018 12 around the globe: Maxigesic =5; Maxiclear = 1, Pascomer = 1; NasoS
Slide 7: Financial Performance – Revenue Growth
FINANCIAL PERFORMANCE – REVENUE GROWTH Operating revenue, FY2000 – FY2017 80 For personal use only 70 Operating revenue (NZ$m) 10 year CAGR: 15% 60 50 40 30 20 10 - FY05 FY06 FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY2016 Operating revenue by region FY2017 Operating revenue by region
Slide 8: Financial Performance – Summary Cashflow
FINANCIAL PERFORMANCE – SUMMARY Cashflow NZ$'000's year ended 31 March 2017 2016 For personal use only Net cash used in operating activities (19,062) (13,942) Net cash used in investing activities (1,598) (1,181) Net cash generated from financing activities 9,042 36,705 Net increase in cash (11,618)
Slide 9: Maxigesic Update
MAXIGESIC UPDATE Nordics – launch pending Eastern Europe and Balkans – launches pending BE/LX & FR– launches pending Italy – successful launch and UK – launched sales increasing significantly For personal use only IE – launch pending Kuwait and Iraq launch pending ES/PT – launch pending UAE – sales
Slide 10: Maxigesic Tablet Sales Progress to Date
For personal use only MAXIGESIC TABLET SALES PROGRESS TO DATE 80,000,000 70,000,000 60,000,000 50,000,000 40,000,000 30,000,000 20,000,000 10,000,000 - FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 All Markets Maxigesic Tablets Sold [Mill] Per Year Note: Only this FY18 year Maxigesic will become AFT’s big
Slide 11: Example of Maxigesic Licensee Progress to Date
EXAMPLE OF MAXIGESIC LICENCEE PROGRESS TO DATE – tablet sales per month For personal use only Maxigesic Sales (Tablets) 900,000 800,000 700,000 600,000 Tablets per Month 500,000 400,000 300,000 200,000 100,000 - Maxigesic Tablets Linear (Maxigesic Tablets) NZSA Meeting 11 19 August 2017
Slide 12: Maxigesic: Future Growth Strategy
MAXIGESIC: Future growth strategy Additional out-licensing and distribution agreements for Maxigesic oral dose forms have been secured to increase For personal use only the number of countries to 124. Some additional larger countries to be added – North America larger EU market France [2nd largest m
Slide 13: Maxigesic: Australian Growth Strategy
For personal use only MAXIGESIC: Australian growth strategy • Prior to the re-scheduling of codeine-based analgesics, our growth estimates were for sales increasing in Australia from 13 to 26 million tablets in FY2018. • Codeine switch confirmed for 1st February 2018. • Codeine tablet market is 750
Slide 14: NasoSURF Nebuliser: Future Growth Strategy
NASOSURF NEBULISER: Future growth strategy A handheld ultrasonic nasal mesh nebuliser for the Product intranasal delivery of medication and treatment of chronic description For personal use only sinusitis The NasoSURF Nebuliser has desirable features over currently marketed nebulisers, which are not
Slide 15: Summary of Medium Term Plans
SUMMARY OF MEDIUM TERM PLANS Phased launches of Maxigesic in over 110 countries including North America For personal use only Add additional Maxigesic dose forms to the initial launches to extend sales Further licensing agreements and more significant upfront licensing fees for Maxigesic and Maxiges